Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.73 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.73 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010724 | 0.84 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL1009815 | 0.84 | MTNR1A (0.75) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL21951952 | 0.78 | MTNR1A (0.65) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL17743971 | 0.77 | POLB (0.49) | HTR2C | |
| SCHEMBL16794999 | 0.76 | HTR2A (0.46) | MTNR1AMTNR1BHTR2C | |
| Hydrochloric Acid SCHEMBL21951934 | 0.76 | MTNR1A (0.62) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL1010476 | 0.74 | MTNR1A (0.61) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL25236273 | 0.74 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2B | |
| SCHEMBL30630329 | 0.74 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2B | |
| SCHEMBL27085142 | 0.74 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3194367-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | Boehringer Ingelheim International GmbH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-9340510-B2 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| WO-2016041845-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | QDPR, RECQL, TPMT | MTNR1A 353/4885MTNR1B 182/4885HTR2C 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.